JP2023529152A5 - - Google Patents

Info

Publication number
JP2023529152A5
JP2023529152A5 JP2022574660A JP2022574660A JP2023529152A5 JP 2023529152 A5 JP2023529152 A5 JP 2023529152A5 JP 2022574660 A JP2022574660 A JP 2022574660A JP 2022574660 A JP2022574660 A JP 2022574660A JP 2023529152 A5 JP2023529152 A5 JP 2023529152A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
fragment
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022574660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/036104 external-priority patent/WO2021248111A1/en
Publication of JP2023529152A publication Critical patent/JP2023529152A/ja
Publication of JP2023529152A5 publication Critical patent/JP2023529152A5/ja
Withdrawn legal-status Critical Current

Links

JP2022574660A 2020-06-06 2021-06-07 コロナウイルス感染を含むウイルス感染を阻害するための物質および方法 Withdrawn JP2023529152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035733P 2020-06-06 2020-06-06
US63/035,733 2020-06-06
PCT/US2021/036104 WO2021248111A1 (en) 2020-06-06 2021-06-07 Materials and methods for inhibiting a viral infection, including a coronavirus infection

Publications (2)

Publication Number Publication Date
JP2023529152A JP2023529152A (ja) 2023-07-07
JP2023529152A5 true JP2023529152A5 (cg-RX-API-DMAC7.html) 2024-06-11

Family

ID=78831585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574660A Withdrawn JP2023529152A (ja) 2020-06-06 2021-06-07 コロナウイルス感染を含むウイルス感染を阻害するための物質および方法

Country Status (11)

Country Link
US (3) US11826390B2 (cg-RX-API-DMAC7.html)
EP (1) EP4161558A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023529152A (cg-RX-API-DMAC7.html)
KR (1) KR20230025853A (cg-RX-API-DMAC7.html)
CN (1) CN116133669A (cg-RX-API-DMAC7.html)
AU (1) AU2021286002A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024911A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180737A1 (cg-RX-API-DMAC7.html)
IL (1) IL298401A (cg-RX-API-DMAC7.html)
MX (1) MX2022015439A (cg-RX-API-DMAC7.html)
WO (1) WO2021248111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293368B2 (en) * 2019-11-26 2026-05-01 Quorum Innovations Llc New barrier and protective preparations and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
KR101300086B1 (ko) 2005-10-06 2013-08-30 프로비 아베 자가면역질환의 치료를 위한 락토바실러스의 용도
AU2008361375B2 (en) * 2008-09-04 2014-05-22 Om Pharma Immunomodulatory extracts from Lactobacillus bacteria and methods of manufacturing and use thereof
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
WO2017015275A1 (en) * 2015-07-20 2017-01-26 Quorum Innovations, Llc Materials and methods for improving immune responses and the skin and/or mucosal barrier function
CN109562140B (zh) 2016-06-03 2023-01-03 霍夫耳科研究所 用于内耳感觉毛细胞再生/替换的联合疗法
US12195502B2 (en) * 2020-05-06 2025-01-14 Quorum Innovations, Llc Protein, and therapeutic and cosmetic uses thereof

Similar Documents

Publication Publication Date Title
RU2016109940A (ru) Вакцина против бешенства
Matveeva et al. Mechanisms of oncolysis by paramyxovirus Sendai
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
AR079555A1 (es) Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv)
MXPA05005203A (es) Vacuna contra vhc.
Masci et al. New and modified interferon alfas: preclinical and clinical data
JP2023527791A5 (cg-RX-API-DMAC7.html)
CN111714621A (zh) 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
JP2019520392A5 (cg-RX-API-DMAC7.html)
JP5209462B2 (ja) コンセンサスインターフェロンの使用方法
WO2017222295A1 (ko) 김치 및 된장 유래 젖산균을 유효성분으로 포함하는 인플루엔자 바이러스 예방 및 치료용 조성물
US8075877B2 (en) Broad spectrum immune and antiviral gene modulation by oral interferon
CA2644670A1 (en) Broad spectrum immune and antiviral gene modulation by oral interferon
MX2024003690A (es) Oligonucleótidos antisentido que tienen una o más unidades abásicas.
JP2011521648A5 (cg-RX-API-DMAC7.html)
KR101329348B1 (ko) 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스
JP2007516214A5 (cg-RX-API-DMAC7.html)
JP2008503569A5 (cg-RX-API-DMAC7.html)
RU2318872C2 (ru) Рекомбинантные штаммы вируса гриппа, экспрессирующие микобактериальный протективный антиген esat-6, и их использование для профилактики и лечения туберкулеза
MX2022004399A (es) Metodos para tratar infecciones viricas por hepatitis delta.
JP2012504941A5 (cg-RX-API-DMAC7.html)
KR102616012B1 (ko) 당화된 돼지 인터페론-알파를 발현하는 재조합 베큘로바이러스
KR100805996B1 (ko) 항-바이러스 의약 및 항암 의약을 제조하기 위한파라폭스바이러스 오비스 균주의 용도
CN117460533A (zh) 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用